Revelation Biosciences, Inc.
REVB
$1.13
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 6.73% | 57.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.26% | 32.35% | |||
| Operating Income | -20.26% | -32.35% | |||
| Income Before Tax | -19.84% | -31.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.84% | -31.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.84% | -31.66% | |||
| EBIT | -20.26% | -32.35% | |||
| EBITDA | -20.25% | -32.51% | |||
| EPS Basic | -64.44% | 76.71% | |||
| Normalized Basic EPS | 43.07% | 42.88% | |||
| EPS Diluted | -64.44% | 76.71% | |||
| Normalized Diluted EPS | 43.07% | 42.88% | |||
| Average Basic Shares Outstanding | 110.48% | 130.49% | |||
| Average Diluted Shares Outstanding | 110.48% | 130.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||